Key result
Diastolic dysfunction affects ~47% of COPD patients, increasing with more advanced GOLD stage.
Why the study?
Suspecting HFpEF in COPD is challenging due to overlapping clinical features, and although echocardiographic assessment of diastolic dysfunction may help identify patients who warrant further cardiac evaluation, the pooled prevalence of diastolic dysfunction among COPD patients required estimation.
Meta-Analysis (n=6,845)
Answers are grounded in this paper and cite their sources.
Echocardiographic diastolic dysfunction is present in approximately 47% of COPD patients and increases with GOLD stage severity, though substantial study heterogeneity and low study quality limit certainty.
Background Given the similarity of risk factors and pathophysiological mechanisms, suspecting HFpEF in COPD is challenging because of overlapping clinical features. Echocardiographic assessment of diastolic dysfunction (DD) may help identify patients with abnormal left ventricular filling who warrant further cardiac evaluation, although DD is not equivalent to a clinical diagnosis of HFpEF. We conducted a systematic review and meta‐analysis to estimate the pooled prevalence of DD among patients with COPD. Methods PubMed, EMBASE, Scopus, and Cochrane databases were searched from inception to February 5, 2026. Studies reporting the prevalence of DD in COPD using any echocardiographic criteria were included. A random‐effects meta‐analysis was performed using restricted maximum‐likelihood estimation. Heterogeneity was assessed with Cochran′s Q , I 2 , and τ 2 . Subgroup, sensitivity, and meta‐regression analyses were conducted. Study quality was assessed using the Newcastle–Ottawa scale, and the certainty of the evidence was evaluated using the GRADE approach. Results Forty‐eight studies comprising 6845 patients were included. The pooled prevalence of echocardiographic findings consistent with DD was 47% (95% CI: 39%–56%), with substantial between‐study heterogeneity ( I 2 = 95.5%; 95% prediction interval, 7%–91%). Prevalence increased across GOLD stages, from 30% (95% CI: 16%–50%) in Stage I to 38% (22%–57%) in Stage II, 58% (39%–75%) in Stage III and 72% (56%–84%) in Stage IV. These stage‐specific estimates were interpreted descriptively because several studies contributed data to multiple stages. Sensitivity analyses yielded pooled prevalences of 54% after excluding low‐quality studies and 62% after excluding studies with fewer than 50 participants. Multivariable meta‐regression explained only a modest proportion of between‐study variance. No statistically significant asymmetry was detected by Egger′s test, although its interpretation for prevalence outcomes is limited. Overall certainty of evidence was low. Conclusions Echocardiographic findings consistent with DD are frequently reported among patients with COPD, but the absolute pooled prevalence is uncertain because of substantial heterogeneity, variation in echocardiographic definitions and predominantly low study quality. A severity‐associated increase across GOLD stages was observed but should be interpreted descriptively because of nonindependent subgroup data. Further prospective studies using standardized echocardiographic definitions and comprehensive cardiopulmonary phenotyping are required.
No takes yet. Share an insight, caveat, or question.
Singhal et al. (2026) conducted a meta-analysis in Chronic obstructive pulmonary disease (COPD) (n=6,845). Chronic obstructive pulmonary disease (COPD) evaluated by echocardiography was evaluated on Pooled prevalence of echocardiographic findings consistent with diastolic dysfunction (Prevalence 47%, 95% CI 39%-56%). Patients with COPD had a 47% pooled prevalence of echocardiographic diastolic dysfunction, rising from 30% in GOLD Stage I to 72% in Stage IV.
Synapse has enriched 10 related papers. Consider them for comparative context: